Neurology Central

AAIC 2018: BAN2401 yields promising results in Alzheimer’s disease treatment

Researchers from Eisai (Tokyo, Japan) and Biogen (MA, USA) have revealed the results of a recent study that suggests that patients given the highest doses of BAN2401 showed significantly slowed cognitive decline, as well as a reduction in amyloid plaques. This research could potentially bring about a promising new treatment for Alzheimer’s disease (AD).

AD is becoming an increasingly widespread disease, with a huge emotional, as well as financial burden on the patients and their families. Because of this, uncovering a new and effective treatment for dementia patients is of high global priority.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.